15,847 Shares in Natera, Inc. $NTRA Acquired by Eagle Health Investments LP

Eagle Health Investments LP acquired a new stake in shares of Natera, Inc. (NASDAQ:NTRA) during the second quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund acquired 15,847 shares of the medical research company’s stock, valued at approximately $4,302,000. Natera makes up about 0.7% of Eagle Health Investments LP’s investment portfolio, making the stock its 23rd largest position.

Several other large investors have also recently added to or reduced their stakes in the stock. BlackRock Inc. purchased a new stake in Natera in the 2nd quarter worth approximately $2,962,770,000. Coatue Management LLC grew its holdings in shares of Natera by 1,446.1% during the 4th quarter. Coatue Management LLC now owns 2,633,334 shares of the medical research company’s stock valued at $603,270,000 after acquiring an additional 2,463,008 shares in the last quarter. Wellington Management Group LLP grew its holdings in shares of Natera by 94.7% during the 4th quarter. Wellington Management Group LLP now owns 4,976,325 shares of the medical research company’s stock valued at $1,140,026,000 after acquiring an additional 2,420,263 shares in the last quarter. Norges Bank acquired a new position in shares of Natera in the fourth quarter worth $372,398,000. Finally, JPMorgan Chase & Co. raised its holdings in shares of Natera by 10.5% during the fourth quarter. JPMorgan Chase & Co. now owns 12,854,334 shares of the medical research company’s stock worth $2,944,800,000 after acquiring an additional 1,225,420 shares in the last quarter. Institutional investors and hedge funds own 99.90% of the company’s stock.

Natera Trading Up 4.3%

Shares of NASDAQ:NTRA opened at $325.07 on Thursday. The stock has a market capitalization of $46.86 billion, a PE ratio of -239.02 and a beta of 1.51. Natera, Inc. has a 1 year low of $156.71 and a 1 year high of $326.03. The firm has a fifty day moving average price of $269.73 and a 200 day moving average price of $228.01.

Natera (NASDAQ:NTRA) last posted its earnings results on Thursday, August 6th. The medical research company reported ($0.47) earnings per share for the quarter, beating the consensus estimate of ($0.49) by $0.02. Natera had a negative return on equity of 11.38% and a negative net margin of 7.11%.The company had revenue of $752.75 million for the quarter, compared to analyst estimates of $661.24 million. During the same period last year, the company earned ($0.74) earnings per share. The business’s revenue was up 37.7% compared to the same quarter last year. On average, sell-side analysts forecast that Natera, Inc. will post -1.02 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of analysts recently issued reports on NTRA shares. Evercore reissued an “outperform” rating and set a $300.00 price objective on shares of Natera in a research report on Monday, July 6th. TD Cowen raised their price target on Natera from $325.00 to $340.00 and gave the stock a “buy” rating in a research note on Friday, August 7th. Canaccord Genuity Group set a $375.00 price target on Natera in a report on Friday, August 7th. Wolfe Research started coverage on Natera in a research note on Tuesday, June 2nd. They issued an “outperform” rating and a $260.00 price target for the company. Finally, Wall Street Zen downgraded Natera from a “buy” rating to a “hold” rating in a report on Saturday, May 9th. Two equities research analysts have rated the stock with a Strong Buy rating, fifteen have issued a Buy rating, four have assigned a Hold rating and one has given a Sell rating to the stock. According to MarketBeat, Natera has a consensus rating of “Moderate Buy” and a consensus price target of $319.38.

Insider Buying and Selling at Natera

In related news, CEO Steven Leonard Chapman sold 41,124 shares of the firm’s stock in a transaction that occurred on Thursday, June 4th. The stock was sold at an average price of $221.03, for a total value of $9,089,637.72. Following the transaction, the chief executive officer directly owned 108,743 shares of the company’s stock, valued at approximately $24,035,465.29. This trade represents a 27.44% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Solomon Moshkevich sold 3,410 shares of the business’s stock in a transaction that occurred on Monday, August 3rd. The stock was sold at an average price of $265.58, for a total value of $905,627.80. Following the completion of the sale, the insider owned 129,019 shares of the company’s stock, valued at approximately $34,264,866.02. This trade represents a 2.57% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders have sold a total of 181,045 shares of company stock worth $41,330,968 in the last 90 days. Company insiders own 5.05% of the company’s stock.

About Natera

Natera is a global diagnostics company that develops and commercializes cell-free DNA and other genetic testing technologies for clinical applications. The company focuses on three principal areas: reproductive health (including non-invasive prenatal testing and carrier screening), oncology (tumor-informed assays for minimal residual disease and recurrence monitoring), and organ transplantation (cell-free DNA tests to detect allograft injury). Natera combines laboratory testing, proprietary bioinformatics, and clinical reporting to deliver personalized genetic information to clinicians and patients.

Key product offerings include Panorama, a non-invasive prenatal test that screens for fetal chromosomal abnormalities and select single-gene conditions; Horizon carrier screening for inherited conditions; Signatera, a personalized, tumor-informed assay used for detecting minimal residual disease and monitoring treatment response in cancer patients; and Prospera, a donor-derived cell-free DNA test used to assess the risk of organ rejection.